Rare Disease Research Teams Receive Over $17m In Funding PDF Print E-mail
Thursday, 08 March 2012 09:08
The Canadian Institutes for Health Research (CIHR) has formed 9 new research teams that will focus on rare diseases. Funding from the CIHR will total $15.4 million over five years, primarily through the Institute of Genetics and the Institute of Nutrition, Metabolism, and Diabetes, while funding from partners will total an additional Total Partner Funding: $1.85 million, also over five years.

The overall objective is to transform fundamental biological research into medical practice and treatments in the area of rare diseases. For example, one team is conducting research on Fabry disease, a rare condition that affects many organ systems. This team will conduct a clinical research trial involving gene therapy, with the ultimate goal of establishing an effective treatment for this disease. The 9 collaborative research teams will investigate a range of issues related to rare diseases, including basic biological science, health services, and policies.

Project titles and funding amounts are as follows:
  • Developing a Canadian framework for evaluation and decision-making for expensive drugs for rare diseases through innovation, value, and priority setting. CIHR: $1,466,018
  • Developing Effective Policies for Managing Technologies for Rare Diseases. CIHR: $1,450,166
  • Emerging team in rare diseases: Achieving the "triple aim" for inborn errors of metabolism. CIHR: $1,490,492
  • Emerging Team: The Scleroderma Patient-centered Intervention Network. CIHR: $1,499,765
  • The FACTs Project: Fabry disease Clinical research and Therapeutics. CIHR: $2,450,000. Kidney Foundation of Canada: $50,000
  • New emerging team on Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS): From models to treatment strategies. CIHR: $1,250,000. Ataxia of Charlevoix-Saguenay Foundation: $1,250,000
  • Chronic childhood vasculitis: Characterizing the individual rare diseases to improve patient outcomes. CIHR: $2,375,000. Canadian Organization for Rare Disorders: $125,000
  • Choroideremia: Expanding our understanding, exploring treatments. CIHR: $930,305. The Choroideremia Research Foundation Canada: $125,000. The Foundation Fighting Blindness: $300,000
  • Emerging Team to identify and characterize novel and existing Hereditary Spastic Paraplegia (HSP) disease genes. CIHR: $2,498,718

“CIHR is pleased to support these new research teams,” said Dr Lasko, scientific director of the CIHR Institute of Genetics. “This is the first time that Canada has supported interdisciplinary research of this kind, and marks a significant step forward in our country’s contribution to this field of study. It is our hope that this research will produce new practices, policies, and treatments that will transform the lives of Canadians living with rare diseases.”

“Canada has excellent researchers and we are delighted that they will now have the opportunity to focus on rare diseases,” said Dr Wong-Rieger, president of the Canadian Organization for Rare Disorders. “This CIHR research announcement will help ensure that Canada is contributing to improving the lives of not only Canadians, but all people living with rare disorders. The Canadian Organization for Rare Disorders is pleased to be a partner in supporting the research and a partner in some of the projects.”

A rare disease is one that affects a small number of people, when compared to the general population. In general, a disease is considered rare when it affects less than one in 2,000 people. They are often chronic diseases and life-threatening. For many rare diseases, signs may be observed at birth or in childhood, as in proximal spinal muscular atrophy, neurofibromatosis, osteogenesis imperfecta, chondrodysplasia or Rett syndrome. However, more than 50% of rare diseases only appear during adulthood, such as Huntington disease, Crohn’s disease, Charcot-Marie-Tooth disease, amyotrophic lateral sclerosis, Kaposi’s sarcoma, or thyroid cancer.

Lad Product News (2012), "Research teams to probe rare diseases with $17M funding", LabCanada.com

 
More articles :

» Cytokines in Systemic Sclerosis: Focus on IL-17

Julie Baraut, Dominique Farge, Elena Ivan-Grigore, Franck Verrecchia, and Laurence MichelSystemic sclerosis (SSc) is an autoimmune disease characterized by progressive sclerosis of the skin and internal organ dysfunction. Cytokine production and...

» arGentis Continues To Expand

But arGentis grew its drug-development pipeline this month with the acquisition of the rights to a rheumatoid arthritis therapy from the - the terms of which, were not disclosed. The treatment was developed at the University of Tennessee Health...

» Toll-like receptor 7 (TLR7)–Driven Accumulation of a Novel CD11c+ B-cell Population is Important for the Development of Autoimmunity

Anatoly V. Rubtsov, Kira Rubtsova, Aryeh Fischer, Richard T. Meehan, Joann Z. Gillis, John W. Kapple, and Philippa MarrackThe American Society of HematologyFemales are more susceptible than males to many autoimmune diseases. The processes causing...

» Important Information About Autoimmune Diseases

There are more than 100 known autoimmune disorders, including rheumatoid arthritis, type 1 diabetes, scleroderma, and lupus. Normally, your immune system is designed to protect your health. But in some people, the immune system creates...

» Scleroderma Drug In Development

According to , has partnered with , the health care investment arm of Morgan Keegan and Co. Inc., to jump-start a capital campaign to raise $12 million to $15 million. ArGentis shelved the campaign last year when the economy soured.The money will...

» Systemic Sclerosis (Scleroderma)

Panayiotis G. Vlachoyiannopoulos1November 2001Systemic sclerosis (SSc) is an autoimmune systemic disease characterized by small vessel involvement that leads to tissue ischemia and fibroblast stimulation resulting in accumulation of collagen...